Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2021 08:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

WATERTOWN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
November 17, 2021 08:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
November 12, 2021 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
November 10, 2021 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update

Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in...
November 04, 2021 08:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting

WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
November 01, 2021 08:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
October 27, 2021 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers

Mean IRAK4 degradation of up to 96% in PBMC and up to 97% inhibition of ex vivo induction of multiple proinflammatory cytokines observed, suggesting potential for broad anti-inflammatory effect ...
October 20, 2021 08:00 ET | Source: Kymera Therapeutics, Inc.

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th

WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
October 13, 2021 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit

WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel...
September 02, 2021 08:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present at Upcoming September Investor Conferences

WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...